The strength of the life science industry
The strength of the life science industry here and the quality of its technologies. We anticipate that internationally competitive Canadian companies will do well having a fund of this size and calibre at their doorstep, and we believe such a fund will energize the sector and be a magnet for further capital."
Announced Date | Fund Name | Money Raised | |
---|---|---|---|
Oct 17, 2016 | Global Health Sciences Venture Fund | $500M |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 15, 2021
Variantyx
|
Series C | $20M | Biotechnology | Yes |
Mar 15, 2021
EyeYon
|
Series C | $25M | Health Care | — |
Mar 11, 2021
CalciMedica
|
Series D | $21M | Health Care | Yes |
May 20, 2020
ARTMS
|
Series A | $19M | Health Care | — |
Mar 4, 2020
Keros Therapeutics
|
Series C | $56M | Biotechnology | — |
Global health sciences venture fund has had 2 exits. Global health sciences venture fund most notable exits include SQZ Biotech , Keros Therapeutics
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Oct 29, 2020 | SQZ Biotech | IPO | Biotechnology | Detail |
Apr 7, 2020 | Keros Therapeutics | IPO | Biotechnology | Detail |